nodes	percent_of_prediction	percent_of_DWPC	metapath
Lenalidomide—PTGS2—Triamcinolone—ankylosing spondylitis	0.127	0.203	CbGbCtD
Lenalidomide—PTGS2—Sulfasalazine—ankylosing spondylitis	0.127	0.203	CbGbCtD
Lenalidomide—PTGS2—Betamethasone—ankylosing spondylitis	0.109	0.175	CbGbCtD
Lenalidomide—PTGS2—Dexamethasone—ankylosing spondylitis	0.0635	0.102	CbGbCtD
Lenalidomide—ABCB1—Methylprednisolone—ankylosing spondylitis	0.0554	0.0886	CbGbCtD
Lenalidomide—TNFSF11—skeletal joint—ankylosing spondylitis	0.0467	0.331	CbGeAlD
Lenalidomide—ABCB1—Betamethasone—ankylosing spondylitis	0.036	0.0576	CbGbCtD
Lenalidomide—ABCB1—Prednisolone—ankylosing spondylitis	0.0355	0.0568	CbGbCtD
Lenalidomide—TNFSF11—synovial membrane of synovial joint—ankylosing spondylitis	0.0355	0.252	CbGeAlD
Lenalidomide—ABCB1—Prednisone—ankylosing spondylitis	0.0336	0.0537	CbGbCtD
Lenalidomide—TNFSF11—cartilage tissue—ankylosing spondylitis	0.0314	0.223	CbGeAlD
Lenalidomide—ABCB1—Dexamethasone—ankylosing spondylitis	0.0209	0.0335	CbGbCtD
Lenalidomide—ABCB1—Methotrexate—ankylosing spondylitis	0.0168	0.0269	CbGbCtD
Lenalidomide—PTGS2—skeletal joint—ankylosing spondylitis	0.00608	0.0431	CbGeAlD
Lenalidomide—TNFSF11—tendon—ankylosing spondylitis	0.00537	0.0381	CbGeAlD
Lenalidomide—Pomalidomide—TNF—ankylosing spondylitis	0.00512	0.608	CrCbGaD
Lenalidomide—PTGS2—synovial membrane of synovial joint—ankylosing spondylitis	0.00462	0.0327	CbGeAlD
Lenalidomide—PTGS2—cartilage tissue—ankylosing spondylitis	0.00409	0.029	CbGeAlD
Lenalidomide—CDH5—tendon—ankylosing spondylitis	0.00404	0.0286	CbGeAlD
Lenalidomide—Thalidomide—TNF—ankylosing spondylitis	0.0033	0.392	CrCbGaD
Lenalidomide—CRBN—tendon—ankylosing spondylitis	0.00257	0.0182	CbGeAlD
Lenalidomide—PTGS2—Fluocinonide—Methylprednisolone—ankylosing spondylitis	0.000902	0.159	CbGdCrCtD
Lenalidomide—PTGS2—Fluocinonide—Dexamethasone—ankylosing spondylitis	0.000888	0.156	CbGdCrCtD
Lenalidomide—PTGS2—Fluocinonide—Betamethasone—ankylosing spondylitis	0.000888	0.156	CbGdCrCtD
Lenalidomide—PTGS2—Fluocinonide—Triamcinolone—ankylosing spondylitis	0.000868	0.153	CbGdCrCtD
Lenalidomide—PTGS2—tendon—ankylosing spondylitis	0.000699	0.00495	CbGeAlD
Lenalidomide—PTGS2—Fluticasone Propionate—Methylprednisolone—ankylosing spondylitis	0.000544	0.0957	CbGdCrCtD
Lenalidomide—PTGS2—Fluticasone Propionate—Dexamethasone—ankylosing spondylitis	0.000536	0.0942	CbGdCrCtD
Lenalidomide—PTGS2—Fluticasone Propionate—Betamethasone—ankylosing spondylitis	0.000536	0.0942	CbGdCrCtD
Lenalidomide—PTGS2—Fluticasone Propionate—Triamcinolone—ankylosing spondylitis	0.000524	0.0921	CbGdCrCtD
Lenalidomide—Infection—Methylprednisolone—ankylosing spondylitis	0.000138	0.00063	CcSEcCtD
Lenalidomide—Haematuria—Methotrexate—ankylosing spondylitis	0.000138	0.000627	CcSEcCtD
Lenalidomide—Shock—Triamcinolone—ankylosing spondylitis	0.000137	0.000625	CcSEcCtD
Lenalidomide—Insomnia—Prednisolone—ankylosing spondylitis	0.000137	0.000625	CcSEcCtD
Lenalidomide—Alopecia—Prednisone—ankylosing spondylitis	0.000137	0.000625	CcSEcCtD
Lenalidomide—Shock—Methylprednisolone—ankylosing spondylitis	0.000137	0.000624	CcSEcCtD
Lenalidomide—Hepatobiliary disease—Methotrexate—ankylosing spondylitis	0.000137	0.000622	CcSEcCtD
Lenalidomide—Nervous system disorder—Methylprednisolone—ankylosing spondylitis	0.000136	0.000622	CcSEcCtD
Lenalidomide—Loss of consciousness—Betamethasone—ankylosing spondylitis	0.000136	0.000621	CcSEcCtD
Lenalidomide—Loss of consciousness—Dexamethasone—ankylosing spondylitis	0.000136	0.000621	CcSEcCtD
Lenalidomide—Epistaxis—Methotrexate—ankylosing spondylitis	0.000136	0.000621	CcSEcCtD
Lenalidomide—Paraesthesia—Prednisolone—ankylosing spondylitis	0.000136	0.000621	CcSEcCtD
Lenalidomide—Tachycardia—Triamcinolone—ankylosing spondylitis	0.000136	0.00062	CcSEcCtD
Lenalidomide—Mental disorder—Prednisone—ankylosing spondylitis	0.000136	0.000619	CcSEcCtD
Lenalidomide—Tachycardia—Methylprednisolone—ankylosing spondylitis	0.000136	0.000619	CcSEcCtD
Lenalidomide—Skin disorder—Methylprednisolone—ankylosing spondylitis	0.000135	0.000616	CcSEcCtD
Lenalidomide—Erythema—Prednisone—ankylosing spondylitis	0.000135	0.000615	CcSEcCtD
Lenalidomide—Malnutrition—Prednisone—ankylosing spondylitis	0.000135	0.000615	CcSEcCtD
Lenalidomide—Hyperhidrosis—Triamcinolone—ankylosing spondylitis	0.000135	0.000614	CcSEcCtD
Lenalidomide—Agranulocytosis—Methotrexate—ankylosing spondylitis	0.000135	0.000614	CcSEcCtD
Lenalidomide—Hyperhidrosis—Methylprednisolone—ankylosing spondylitis	0.000135	0.000613	CcSEcCtD
Lenalidomide—Hypertension—Betamethasone—ankylosing spondylitis	0.000134	0.00061	CcSEcCtD
Lenalidomide—Hypertension—Dexamethasone—ankylosing spondylitis	0.000134	0.00061	CcSEcCtD
Lenalidomide—Myalgia—Dexamethasone—ankylosing spondylitis	0.000132	0.000602	CcSEcCtD
Lenalidomide—Myalgia—Betamethasone—ankylosing spondylitis	0.000132	0.000602	CcSEcCtD
Lenalidomide—Anxiety—Dexamethasone—ankylosing spondylitis	0.000132	0.000599	CcSEcCtD
Lenalidomide—Anxiety—Betamethasone—ankylosing spondylitis	0.000132	0.000599	CcSEcCtD
Lenalidomide—Discomfort—Dexamethasone—ankylosing spondylitis	0.00013	0.000594	CcSEcCtD
Lenalidomide—Discomfort—Betamethasone—ankylosing spondylitis	0.00013	0.000594	CcSEcCtD
Lenalidomide—Haemoglobin—Methotrexate—ankylosing spondylitis	0.00013	0.000594	CcSEcCtD
Lenalidomide—Hypotension—Methylprednisolone—ankylosing spondylitis	0.00013	0.000593	CcSEcCtD
Lenalidomide—Pain—Prednisolone—ankylosing spondylitis	0.00013	0.000591	CcSEcCtD
Lenalidomide—Haemorrhage—Methotrexate—ankylosing spondylitis	0.00013	0.000591	CcSEcCtD
Lenalidomide—Hepatitis—Methotrexate—ankylosing spondylitis	0.00013	0.000591	CcSEcCtD
Lenalidomide—Pharyngitis—Methotrexate—ankylosing spondylitis	0.000129	0.000586	CcSEcCtD
Lenalidomide—Urinary tract disorder—Methotrexate—ankylosing spondylitis	0.000128	0.000583	CcSEcCtD
Lenalidomide—Vision blurred—Prednisone—ankylosing spondylitis	0.000127	0.00058	CcSEcCtD
Lenalidomide—Urethral disorder—Methotrexate—ankylosing spondylitis	0.000127	0.000579	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Triamcinolone—ankylosing spondylitis	0.000127	0.000579	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Methylprednisolone—ankylosing spondylitis	0.000127	0.000578	CcSEcCtD
Lenalidomide—Oedema—Dexamethasone—ankylosing spondylitis	0.000127	0.000577	CcSEcCtD
Lenalidomide—Oedema—Betamethasone—ankylosing spondylitis	0.000127	0.000577	CcSEcCtD
Lenalidomide—Insomnia—Triamcinolone—ankylosing spondylitis	0.000126	0.000575	CcSEcCtD
Lenalidomide—Insomnia—Methylprednisolone—ankylosing spondylitis	0.000126	0.000574	CcSEcCtD
Lenalidomide—Infection—Betamethasone—ankylosing spondylitis	0.000126	0.000573	CcSEcCtD
Lenalidomide—Infection—Dexamethasone—ankylosing spondylitis	0.000126	0.000573	CcSEcCtD
Lenalidomide—Ill-defined disorder—Prednisone—ankylosing spondylitis	0.000125	0.000571	CcSEcCtD
Lenalidomide—Paraesthesia—Triamcinolone—ankylosing spondylitis	0.000125	0.000571	CcSEcCtD
Lenalidomide—Feeling abnormal—Prednisolone—ankylosing spondylitis	0.000125	0.000569	CcSEcCtD
Lenalidomide—Paraesthesia—Methylprednisolone—ankylosing spondylitis	0.000125	0.000569	CcSEcCtD
Lenalidomide—Visual impairment—Methotrexate—ankylosing spondylitis	0.000125	0.000569	CcSEcCtD
Lenalidomide—Anaemia—Prednisone—ankylosing spondylitis	0.000125	0.000569	CcSEcCtD
Lenalidomide—Shock—Dexamethasone—ankylosing spondylitis	0.000125	0.000567	CcSEcCtD
Lenalidomide—Shock—Betamethasone—ankylosing spondylitis	0.000125	0.000567	CcSEcCtD
Lenalidomide—Dyspnoea—Triamcinolone—ankylosing spondylitis	0.000124	0.000567	CcSEcCtD
Lenalidomide—Nervous system disorder—Dexamethasone—ankylosing spondylitis	0.000124	0.000565	CcSEcCtD
Lenalidomide—Nervous system disorder—Betamethasone—ankylosing spondylitis	0.000124	0.000565	CcSEcCtD
Lenalidomide—Agitation—Prednisone—ankylosing spondylitis	0.000124	0.000565	CcSEcCtD
Lenalidomide—Thrombocytopenia—Betamethasone—ankylosing spondylitis	0.000124	0.000565	CcSEcCtD
Lenalidomide—Thrombocytopenia—Dexamethasone—ankylosing spondylitis	0.000124	0.000565	CcSEcCtD
Lenalidomide—Tachycardia—Dexamethasone—ankylosing spondylitis	0.000124	0.000563	CcSEcCtD
Lenalidomide—Tachycardia—Betamethasone—ankylosing spondylitis	0.000124	0.000563	CcSEcCtD
Lenalidomide—Angioedema—Prednisone—ankylosing spondylitis	0.000123	0.000562	CcSEcCtD
Lenalidomide—Dyspepsia—Triamcinolone—ankylosing spondylitis	0.000123	0.000559	CcSEcCtD
Lenalidomide—Erythema multiforme—Methotrexate—ankylosing spondylitis	0.000123	0.000559	CcSEcCtD
Lenalidomide—Dyspepsia—Methylprednisolone—ankylosing spondylitis	0.000123	0.000558	CcSEcCtD
Lenalidomide—Hyperhidrosis—Dexamethasone—ankylosing spondylitis	0.000122	0.000557	CcSEcCtD
Lenalidomide—Hyperhidrosis—Betamethasone—ankylosing spondylitis	0.000122	0.000557	CcSEcCtD
Lenalidomide—Malaise—Prednisone—ankylosing spondylitis	0.000122	0.000555	CcSEcCtD
Lenalidomide—Vertigo—Prednisone—ankylosing spondylitis	0.000121	0.000553	CcSEcCtD
Lenalidomide—Eye disorder—Methotrexate—ankylosing spondylitis	0.000121	0.000552	CcSEcCtD
Lenalidomide—Syncope—Prednisone—ankylosing spondylitis	0.000121	0.000552	CcSEcCtD
Lenalidomide—Tinnitus—Methotrexate—ankylosing spondylitis	0.000121	0.000551	CcSEcCtD
Lenalidomide—Anorexia—Betamethasone—ankylosing spondylitis	0.000121	0.00055	CcSEcCtD
Lenalidomide—Anorexia—Dexamethasone—ankylosing spondylitis	0.000121	0.00055	CcSEcCtD
Lenalidomide—Urticaria—Prednisolone—ankylosing spondylitis	0.000121	0.000549	CcSEcCtD
Lenalidomide—Cardiac disorder—Methotrexate—ankylosing spondylitis	0.00012	0.000548	CcSEcCtD
Lenalidomide—Fatigue—Triamcinolone—ankylosing spondylitis	0.00012	0.000548	CcSEcCtD
Lenalidomide—Fatigue—Methylprednisolone—ankylosing spondylitis	0.00012	0.000547	CcSEcCtD
Lenalidomide—Pain—Triamcinolone—ankylosing spondylitis	0.000119	0.000543	CcSEcCtD
Lenalidomide—Loss of consciousness—Prednisone—ankylosing spondylitis	0.000119	0.000541	CcSEcCtD
Lenalidomide—Hypotension—Dexamethasone—ankylosing spondylitis	0.000118	0.000539	CcSEcCtD
Lenalidomide—Hypotension—Betamethasone—ankylosing spondylitis	0.000118	0.000539	CcSEcCtD
Lenalidomide—Angiopathy—Methotrexate—ankylosing spondylitis	0.000118	0.000536	CcSEcCtD
Lenalidomide—Immune system disorder—Methotrexate—ankylosing spondylitis	0.000117	0.000534	CcSEcCtD
Lenalidomide—Mediastinal disorder—Methotrexate—ankylosing spondylitis	0.000117	0.000532	CcSEcCtD
Lenalidomide—Hypertension—Prednisone—ankylosing spondylitis	0.000117	0.000531	CcSEcCtD
Lenalidomide—Chills—Methotrexate—ankylosing spondylitis	0.000116	0.00053	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Dexamethasone—ankylosing spondylitis	0.000115	0.000525	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Betamethasone—ankylosing spondylitis	0.000115	0.000525	CcSEcCtD
Lenalidomide—Myalgia—Prednisone—ankylosing spondylitis	0.000115	0.000524	CcSEcCtD
Lenalidomide—Arthralgia—Prednisone—ankylosing spondylitis	0.000115	0.000524	CcSEcCtD
Lenalidomide—Feeling abnormal—Triamcinolone—ankylosing spondylitis	0.000115	0.000524	CcSEcCtD
Lenalidomide—Feeling abnormal—Methylprednisolone—ankylosing spondylitis	0.000115	0.000523	CcSEcCtD
Lenalidomide—Anxiety—Prednisone—ankylosing spondylitis	0.000115	0.000522	CcSEcCtD
Lenalidomide—Alopecia—Methotrexate—ankylosing spondylitis	0.000115	0.000522	CcSEcCtD
Lenalidomide—Insomnia—Betamethasone—ankylosing spondylitis	0.000114	0.000522	CcSEcCtD
Lenalidomide—Insomnia—Dexamethasone—ankylosing spondylitis	0.000114	0.000522	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—ankylosing spondylitis	0.000114	0.00052	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Methylprednisolone—ankylosing spondylitis	0.000114	0.000519	CcSEcCtD
Lenalidomide—Paraesthesia—Betamethasone—ankylosing spondylitis	0.000114	0.000518	CcSEcCtD
Lenalidomide—Paraesthesia—Dexamethasone—ankylosing spondylitis	0.000114	0.000518	CcSEcCtD
Lenalidomide—Discomfort—Prednisone—ankylosing spondylitis	0.000114	0.000518	CcSEcCtD
Lenalidomide—Mental disorder—Methotrexate—ankylosing spondylitis	0.000114	0.000518	CcSEcCtD
Lenalidomide—Erythema—Methotrexate—ankylosing spondylitis	0.000113	0.000514	CcSEcCtD
Lenalidomide—Malnutrition—Methotrexate—ankylosing spondylitis	0.000113	0.000514	CcSEcCtD
Lenalidomide—Hypersensitivity—Prednisolone—ankylosing spondylitis	0.000112	0.000509	CcSEcCtD
Lenalidomide—Dyspepsia—Betamethasone—ankylosing spondylitis	0.000111	0.000508	CcSEcCtD
Lenalidomide—Dyspepsia—Dexamethasone—ankylosing spondylitis	0.000111	0.000508	CcSEcCtD
Lenalidomide—Urticaria—Triamcinolone—ankylosing spondylitis	0.000111	0.000505	CcSEcCtD
Lenalidomide—Urticaria—Methylprednisolone—ankylosing spondylitis	0.000111	0.000504	CcSEcCtD
Lenalidomide—Dysgeusia—Methotrexate—ankylosing spondylitis	0.000111	0.000504	CcSEcCtD
Lenalidomide—Body temperature increased—Triamcinolone—ankylosing spondylitis	0.00011	0.000502	CcSEcCtD
Lenalidomide—Oedema—Prednisone—ankylosing spondylitis	0.00011	0.000502	CcSEcCtD
Lenalidomide—Abdominal pain—Methylprednisolone—ankylosing spondylitis	0.00011	0.000501	CcSEcCtD
Lenalidomide—Decreased appetite—Betamethasone—ankylosing spondylitis	0.00011	0.000501	CcSEcCtD
Lenalidomide—Decreased appetite—Dexamethasone—ankylosing spondylitis	0.00011	0.000501	CcSEcCtD
Lenalidomide—Infection—Prednisone—ankylosing spondylitis	0.00011	0.000499	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Dexamethasone—ankylosing spondylitis	0.000109	0.000498	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Betamethasone—ankylosing spondylitis	0.000109	0.000498	CcSEcCtD
Lenalidomide—Back pain—Methotrexate—ankylosing spondylitis	0.000109	0.000497	CcSEcCtD
Lenalidomide—Fatigue—Dexamethasone—ankylosing spondylitis	0.000109	0.000497	CcSEcCtD
Lenalidomide—Fatigue—Betamethasone—ankylosing spondylitis	0.000109	0.000497	CcSEcCtD
Lenalidomide—Shock—Prednisone—ankylosing spondylitis	0.000108	0.000494	CcSEcCtD
Lenalidomide—Pain—Dexamethasone—ankylosing spondylitis	0.000108	0.000493	CcSEcCtD
Lenalidomide—Pain—Betamethasone—ankylosing spondylitis	0.000108	0.000493	CcSEcCtD
Lenalidomide—Nervous system disorder—Prednisone—ankylosing spondylitis	0.000108	0.000492	CcSEcCtD
Lenalidomide—Tachycardia—Prednisone—ankylosing spondylitis	0.000108	0.00049	CcSEcCtD
Lenalidomide—Skin disorder—Prednisone—ankylosing spondylitis	0.000107	0.000488	CcSEcCtD
Lenalidomide—Hyperhidrosis—Prednisone—ankylosing spondylitis	0.000107	0.000485	CcSEcCtD
Lenalidomide—Vision blurred—Methotrexate—ankylosing spondylitis	0.000106	0.000485	CcSEcCtD
Lenalidomide—Anorexia—Prednisone—ankylosing spondylitis	0.000105	0.000479	CcSEcCtD
Lenalidomide—Ill-defined disorder—Methotrexate—ankylosing spondylitis	0.000105	0.000477	CcSEcCtD
Lenalidomide—Anaemia—Methotrexate—ankylosing spondylitis	0.000104	0.000475	CcSEcCtD
Lenalidomide—Feeling abnormal—Betamethasone—ankylosing spondylitis	0.000104	0.000475	CcSEcCtD
Lenalidomide—Feeling abnormal—Dexamethasone—ankylosing spondylitis	0.000104	0.000475	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Dexamethasone—ankylosing spondylitis	0.000104	0.000472	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Betamethasone—ankylosing spondylitis	0.000104	0.000472	CcSEcCtD
Lenalidomide—Hypersensitivity—Triamcinolone—ankylosing spondylitis	0.000103	0.000468	CcSEcCtD
Lenalidomide—Hypersensitivity—Methylprednisolone—ankylosing spondylitis	0.000103	0.000467	CcSEcCtD
Lenalidomide—Malaise—Methotrexate—ankylosing spondylitis	0.000102	0.000464	CcSEcCtD
Lenalidomide—Vertigo—Methotrexate—ankylosing spondylitis	0.000101	0.000462	CcSEcCtD
Lenalidomide—Leukopenia—Methotrexate—ankylosing spondylitis	0.000101	0.00046	CcSEcCtD
Lenalidomide—Urticaria—Betamethasone—ankylosing spondylitis	0.000101	0.000458	CcSEcCtD
Lenalidomide—Urticaria—Dexamethasone—ankylosing spondylitis	0.000101	0.000458	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Prednisone—ankylosing spondylitis	0.0001	0.000458	CcSEcCtD
Lenalidomide—Dizziness—Prednisolone—ankylosing spondylitis	0.0001	0.000457	CcSEcCtD
Lenalidomide—Asthenia—Triamcinolone—ankylosing spondylitis	0.0001	0.000456	CcSEcCtD
Lenalidomide—Abdominal pain—Betamethasone—ankylosing spondylitis	0.0001	0.000456	CcSEcCtD
Lenalidomide—Abdominal pain—Dexamethasone—ankylosing spondylitis	0.0001	0.000456	CcSEcCtD
Lenalidomide—Body temperature increased—Betamethasone—ankylosing spondylitis	0.0001	0.000456	CcSEcCtD
Lenalidomide—Body temperature increased—Dexamethasone—ankylosing spondylitis	0.0001	0.000456	CcSEcCtD
Lenalidomide—Asthenia—Methylprednisolone—ankylosing spondylitis	9.99e-05	0.000455	CcSEcCtD
Lenalidomide—Insomnia—Prednisone—ankylosing spondylitis	9.97e-05	0.000454	CcSEcCtD
Lenalidomide—Paraesthesia—Prednisone—ankylosing spondylitis	9.9e-05	0.000451	CcSEcCtD
Lenalidomide—Pruritus—Triamcinolone—ankylosing spondylitis	9.87e-05	0.00045	CcSEcCtD
Lenalidomide—Cough—Methotrexate—ankylosing spondylitis	9.85e-05	0.000449	CcSEcCtD
Lenalidomide—Pruritus—Methylprednisolone—ankylosing spondylitis	9.85e-05	0.000449	CcSEcCtD
Lenalidomide—Dyspepsia—Prednisone—ankylosing spondylitis	9.7e-05	0.000442	CcSEcCtD
Lenalidomide—Myalgia—Methotrexate—ankylosing spondylitis	9.61e-05	0.000438	CcSEcCtD
Lenalidomide—Chest pain—Methotrexate—ankylosing spondylitis	9.61e-05	0.000438	CcSEcCtD
Lenalidomide—Arthralgia—Methotrexate—ankylosing spondylitis	9.61e-05	0.000438	CcSEcCtD
Lenalidomide—Decreased appetite—Prednisone—ankylosing spondylitis	9.58e-05	0.000437	CcSEcCtD
Lenalidomide—Rash—Prednisolone—ankylosing spondylitis	9.56e-05	0.000436	CcSEcCtD
Lenalidomide—Dermatitis—Prednisolone—ankylosing spondylitis	9.56e-05	0.000435	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—ankylosing spondylitis	9.54e-05	0.000435	CcSEcCtD
Lenalidomide—Diarrhoea—Methylprednisolone—ankylosing spondylitis	9.52e-05	0.000434	CcSEcCtD
Lenalidomide—Fatigue—Prednisone—ankylosing spondylitis	9.5e-05	0.000433	CcSEcCtD
Lenalidomide—Headache—Prednisolone—ankylosing spondylitis	9.5e-05	0.000433	CcSEcCtD
Lenalidomide—Discomfort—Methotrexate—ankylosing spondylitis	9.49e-05	0.000433	CcSEcCtD
Lenalidomide—Constipation—Prednisone—ankylosing spondylitis	9.43e-05	0.000429	CcSEcCtD
Lenalidomide—Confusional state—Methotrexate—ankylosing spondylitis	9.29e-05	0.000423	CcSEcCtD
Lenalidomide—Dizziness—Triamcinolone—ankylosing spondylitis	9.22e-05	0.00042	CcSEcCtD
Lenalidomide—Dizziness—Methylprednisolone—ankylosing spondylitis	9.2e-05	0.000419	CcSEcCtD
Lenalidomide—Infection—Methotrexate—ankylosing spondylitis	9.15e-05	0.000417	CcSEcCtD
Lenalidomide—Feeling abnormal—Prednisone—ankylosing spondylitis	9.08e-05	0.000414	CcSEcCtD
Lenalidomide—Asthenia—Betamethasone—ankylosing spondylitis	9.08e-05	0.000414	CcSEcCtD
Lenalidomide—Asthenia—Dexamethasone—ankylosing spondylitis	9.08e-05	0.000414	CcSEcCtD
Lenalidomide—Nervous system disorder—Methotrexate—ankylosing spondylitis	9.03e-05	0.000412	CcSEcCtD
Lenalidomide—Thrombocytopenia—Methotrexate—ankylosing spondylitis	9.02e-05	0.000411	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Prednisone—ankylosing spondylitis	9.01e-05	0.000411	CcSEcCtD
Lenalidomide—Nausea—Prednisolone—ankylosing spondylitis	9.01e-05	0.00041	CcSEcCtD
Lenalidomide—Pruritus—Betamethasone—ankylosing spondylitis	8.95e-05	0.000408	CcSEcCtD
Lenalidomide—Pruritus—Dexamethasone—ankylosing spondylitis	8.95e-05	0.000408	CcSEcCtD
Lenalidomide—Skin disorder—Methotrexate—ankylosing spondylitis	8.95e-05	0.000408	CcSEcCtD
Lenalidomide—Hyperhidrosis—Methotrexate—ankylosing spondylitis	8.91e-05	0.000406	CcSEcCtD
Lenalidomide—Vomiting—Triamcinolone—ankylosing spondylitis	8.87e-05	0.000404	CcSEcCtD
Lenalidomide—Vomiting—Methylprednisolone—ankylosing spondylitis	8.85e-05	0.000403	CcSEcCtD
Lenalidomide—Rash—Triamcinolone—ankylosing spondylitis	8.8e-05	0.000401	CcSEcCtD
Lenalidomide—Dermatitis—Triamcinolone—ankylosing spondylitis	8.79e-05	0.0004	CcSEcCtD
Lenalidomide—Anorexia—Methotrexate—ankylosing spondylitis	8.78e-05	0.0004	CcSEcCtD
Lenalidomide—Rash—Methylprednisolone—ankylosing spondylitis	8.78e-05	0.0004	CcSEcCtD
Lenalidomide—Dermatitis—Methylprednisolone—ankylosing spondylitis	8.77e-05	0.000399	CcSEcCtD
Lenalidomide—Urticaria—Prednisone—ankylosing spondylitis	8.76e-05	0.000399	CcSEcCtD
Lenalidomide—Headache—Triamcinolone—ankylosing spondylitis	8.74e-05	0.000398	CcSEcCtD
Lenalidomide—Headache—Methylprednisolone—ankylosing spondylitis	8.72e-05	0.000397	CcSEcCtD
Lenalidomide—Abdominal pain—Prednisone—ankylosing spondylitis	8.71e-05	0.000397	CcSEcCtD
Lenalidomide—Body temperature increased—Prednisone—ankylosing spondylitis	8.71e-05	0.000397	CcSEcCtD
Lenalidomide—Diarrhoea—Betamethasone—ankylosing spondylitis	8.66e-05	0.000395	CcSEcCtD
Lenalidomide—Diarrhoea—Dexamethasone—ankylosing spondylitis	8.66e-05	0.000395	CcSEcCtD
Lenalidomide—Hypotension—Methotrexate—ankylosing spondylitis	8.61e-05	0.000392	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Methotrexate—ankylosing spondylitis	8.39e-05	0.000382	CcSEcCtD
Lenalidomide—Dizziness—Betamethasone—ankylosing spondylitis	8.37e-05	0.000381	CcSEcCtD
Lenalidomide—Dizziness—Dexamethasone—ankylosing spondylitis	8.37e-05	0.000381	CcSEcCtD
Lenalidomide—Insomnia—Methotrexate—ankylosing spondylitis	8.33e-05	0.00038	CcSEcCtD
Lenalidomide—Nausea—Triamcinolone—ankylosing spondylitis	8.29e-05	0.000377	CcSEcCtD
Lenalidomide—Paraesthesia—Methotrexate—ankylosing spondylitis	8.27e-05	0.000377	CcSEcCtD
Lenalidomide—Nausea—Methylprednisolone—ankylosing spondylitis	8.27e-05	0.000377	CcSEcCtD
Lenalidomide—Dyspnoea—Methotrexate—ankylosing spondylitis	8.21e-05	0.000374	CcSEcCtD
Lenalidomide—Somnolence—Methotrexate—ankylosing spondylitis	8.19e-05	0.000373	CcSEcCtD
Lenalidomide—Hypersensitivity—Prednisone—ankylosing spondylitis	8.12e-05	0.00037	CcSEcCtD
Lenalidomide—Dyspepsia—Methotrexate—ankylosing spondylitis	8.11e-05	0.000369	CcSEcCtD
Lenalidomide—Vomiting—Betamethasone—ankylosing spondylitis	8.05e-05	0.000367	CcSEcCtD
Lenalidomide—Vomiting—Dexamethasone—ankylosing spondylitis	8.05e-05	0.000367	CcSEcCtD
Lenalidomide—Decreased appetite—Methotrexate—ankylosing spondylitis	8.01e-05	0.000365	CcSEcCtD
Lenalidomide—Rash—Dexamethasone—ankylosing spondylitis	7.98e-05	0.000364	CcSEcCtD
Lenalidomide—Rash—Betamethasone—ankylosing spondylitis	7.98e-05	0.000364	CcSEcCtD
Lenalidomide—Dermatitis—Dexamethasone—ankylosing spondylitis	7.97e-05	0.000363	CcSEcCtD
Lenalidomide—Dermatitis—Betamethasone—ankylosing spondylitis	7.97e-05	0.000363	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Methotrexate—ankylosing spondylitis	7.95e-05	0.000362	CcSEcCtD
Lenalidomide—Fatigue—Methotrexate—ankylosing spondylitis	7.94e-05	0.000362	CcSEcCtD
Lenalidomide—Headache—Betamethasone—ankylosing spondylitis	7.93e-05	0.000361	CcSEcCtD
Lenalidomide—Headache—Dexamethasone—ankylosing spondylitis	7.93e-05	0.000361	CcSEcCtD
Lenalidomide—Asthenia—Prednisone—ankylosing spondylitis	7.91e-05	0.00036	CcSEcCtD
Lenalidomide—Pain—Methotrexate—ankylosing spondylitis	7.88e-05	0.000359	CcSEcCtD
Lenalidomide—Pruritus—Prednisone—ankylosing spondylitis	7.8e-05	0.000355	CcSEcCtD
Lenalidomide—Feeling abnormal—Methotrexate—ankylosing spondylitis	7.59e-05	0.000346	CcSEcCtD
Lenalidomide—Diarrhoea—Prednisone—ankylosing spondylitis	7.54e-05	0.000344	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Methotrexate—ankylosing spondylitis	7.53e-05	0.000343	CcSEcCtD
Lenalidomide—Nausea—Betamethasone—ankylosing spondylitis	7.52e-05	0.000343	CcSEcCtD
Lenalidomide—Nausea—Dexamethasone—ankylosing spondylitis	7.52e-05	0.000343	CcSEcCtD
Lenalidomide—Urticaria—Methotrexate—ankylosing spondylitis	7.32e-05	0.000333	CcSEcCtD
Lenalidomide—Dizziness—Prednisone—ankylosing spondylitis	7.29e-05	0.000332	CcSEcCtD
Lenalidomide—Body temperature increased—Methotrexate—ankylosing spondylitis	7.28e-05	0.000332	CcSEcCtD
Lenalidomide—Abdominal pain—Methotrexate—ankylosing spondylitis	7.28e-05	0.000332	CcSEcCtD
Lenalidomide—Vomiting—Prednisone—ankylosing spondylitis	7.01e-05	0.000319	CcSEcCtD
Lenalidomide—Rash—Prednisone—ankylosing spondylitis	6.95e-05	0.000317	CcSEcCtD
Lenalidomide—Dermatitis—Prednisone—ankylosing spondylitis	6.94e-05	0.000316	CcSEcCtD
Lenalidomide—Headache—Prednisone—ankylosing spondylitis	6.91e-05	0.000315	CcSEcCtD
Lenalidomide—Hypersensitivity—Methotrexate—ankylosing spondylitis	6.79e-05	0.000309	CcSEcCtD
Lenalidomide—Asthenia—Methotrexate—ankylosing spondylitis	6.61e-05	0.000301	CcSEcCtD
Lenalidomide—Nausea—Prednisone—ankylosing spondylitis	6.55e-05	0.000298	CcSEcCtD
Lenalidomide—Pruritus—Methotrexate—ankylosing spondylitis	6.52e-05	0.000297	CcSEcCtD
Lenalidomide—Diarrhoea—Methotrexate—ankylosing spondylitis	6.3e-05	0.000287	CcSEcCtD
Lenalidomide—Dizziness—Methotrexate—ankylosing spondylitis	6.09e-05	0.000278	CcSEcCtD
Lenalidomide—Vomiting—Methotrexate—ankylosing spondylitis	5.86e-05	0.000267	CcSEcCtD
Lenalidomide—Rash—Methotrexate—ankylosing spondylitis	5.81e-05	0.000265	CcSEcCtD
Lenalidomide—Dermatitis—Methotrexate—ankylosing spondylitis	5.8e-05	0.000264	CcSEcCtD
Lenalidomide—Headache—Methotrexate—ankylosing spondylitis	5.77e-05	0.000263	CcSEcCtD
Lenalidomide—Nausea—Methotrexate—ankylosing spondylitis	5.47e-05	0.000249	CcSEcCtD
